G250: A carbonic anhydrase IX monoclonal antibody

Current Oncology Reports

Volumn 7, Issue 2, 2005, Pages 109-115

  Lam, John S ^a   Pantuck, Allan J ^a   Belldegrun, Arie S ^a   Figlin, Robert A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; CARBONATE DEHYDRATASE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 2; IODINE 131; MONOCLONAL ANTIBODY G250;

ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG RESPONSE; DRUG UPTAKE; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER TOXICITY; NONHUMAN; PROGNOSIS; REVIEW; SIDE EFFECT;

EID: 16844370348     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-005-0036-7     Document Type: Review

References (50)

1. Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol 1999, 161:381-386.
2. Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 2001, 166: 611-1623.
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843-852.
4. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408-417.
5. Pantuck AJ, Belldegrun AS, Figlin RA: Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001, 345:1711-1712.
6. Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655-1659.
7. Mickisch GH, Garin A, van Poppel H, et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966-970.
8. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al.: Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986, 38:489-494.
9. Liao SY, Aurelio ON, Jan K, et al.: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997, 57:2827-2831.
10. Pastorek J, Pastorekova S, Callebaut I, et al.: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9:2877-2888.
11. Opavsky R, Pastorekova S, Zelnik V, et al.: Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996, 33: 80-487.
12. Pastorekova S, Parkkila S, Parkkila AK, et al.: Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112:398-408.
13. Gut MO, Parkkila S, Vernerova Z, et al.: Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002, 123:1889-1903.
14. Ivanov S, Liao SY, Ivanova A, et al.: Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001, 158:905-919.
15. Loncaster JA, Harris AL, Davidson SE, et al.: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001, 61:6394-6399.
16. Wykoff CC, Beasley NJ, Watson PH, et al.: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60:7075-7083.
17. Harris AL: Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
18. Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8:S62-67.
19. Ivanov SV, Kuzmin I, Wei MH, et al.: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A 1998, 95:12596-12601.
20. Potter C, Harris AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004, 3:164-167.
21. Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802-811.
22. Atkins M, McDermott D, Mier J, et al.: Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy [abstract]. Proc ASCO 2004, 23:383.
23. Grabmaier K, MC AdW, Verhaegh GW, et al.: Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004, 23:5624-5631.
24. Palapattu GS, Reiter RE: Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol 2002, 168:2615-2623.
25. Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
26. Zinkernagel RM, Hengartner H: Regulation of the immune response by antigen. Science 2001, 293:251-253.
27. Wang RF, Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev 1999, 170:85-100.
28. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990, 50:814s-819s.
29. Ueda R, Shiku H, Pfreundschuh M, et al.: Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med 1979, 150:564-579.
30. Lam JS, Belldegrun AS, Figlin RA: Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 2005, in press.
31. Oosterwijk E, Divgi CR, Brouwers A, et al.: Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am 2003, 30:623-631.
32. Finstad CL, Cordon-Cardo C, Bander NH, et al.: Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci U S A 1985, 82:2955-2959.
33. Vessella RL, Moon TD, Chiou RK, et al.: Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens. Cancer Res 1985, 45:6131-6139.
34. Grabmaier K, Vissers JL, De Weijert MC, et al.: Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000, 85:865-870.
35. Kranenborg MH, Boerman OC, de Weijert MC, et al.: The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997, 80:2390-2397.
36. Steffens MG, Kranenborg MH, Boerman OC, et al.: Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm 1998, 13:133-139.
37. van Dijk J, Oosterwijk E, van Kroonenburgh MJ, et al.: Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies. J Nucl Med 1988, 29: 078-1082.
38. van Dijk J, Uemura H, Beniers AJ, et al.: Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994, 56:262-268.
39. van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO: Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 1991, 48: 38-743.
40. Oosterwijk E, Bander NH, Divgi CR, et al.: Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993, 11:738-750.
41. Divgi CR, Bander NH, Scott AM, et al.: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998, 4: 729-2739.
42. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al.: Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997, 15:1529-1537.
43. Steffens MG, Boerman OC, de Mulder PH, et al.: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999, 5: 268s-3274s.
44. Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, et al.: Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 1999, 19:1197-1200.
45. Steffens MG, Boerman OC, Oyen WJ, et al.: Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999, 59: 615-1619.
46. Brouwers AH, van Eerd JE, Frielink C, et al.: Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 2004, 45:327-337.
47. Divgi CR, O'Donoghue JA, Welt S, et al.: Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004, 45:1412-1421.
48. Bleumer I, Knuth A, Oosterwijk E, et al.: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004, 90:985-990.
49. Liu Z, Smyth FE, Renner C, et al.: Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002, 51:171-177.
50. Bevan P, Mala C, Kindler M, et al.: Results of a phase I/II study with monoclonal antibody CG250 in combination with IFNa-2A in metastatic renal cell carcinoma patients [abstract]. Proc ASCO 2004, 23:407.